Russian biotech company Biocad plans to develop and bring to the Chinese market at least six drugs in partnership with the Chinese holding Shanghai Pharmaceuticals. This was announced by Industry and Trade Minister Denis Manturov in Kunming (South-Western China) at the plenary session of the Russian-Chinese subcommittee on cooperation in the field of industry
“The intention to search for common growth points in the innovation sectors, which you mentioned today, we certainly should project to a wider range of industries. In this regard, I would like to refer to the memorandum of understanding signed between the Russian pharmaceutical leader Biocad and the Shanghai Pharmaceuticals holding, signed in Vladivostok a few days ago,” said Mr. Manturov.
“Within the partnership we plan to develop, register and bring to the Chinese market at least six drugs, including those for the treatment of cancer and severe autoimmune diseases – the therapy of lung cancer, breast cancer and psoriasis,” the Minister said.
ZAO Biocad is one of the largest full cycle innovative biotechnology companies in Russia, which is engaged in all stages of medicines development and production. The company employs more than 1.7 thousand people, including 700 scientists and researchers.